Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FHSFR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Site-sepcific ADC 5
|
|||||
| Synonyms |
Site-sepcific ADC 5
Click to Show/Hide
|
|||||
| Organization |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences.; University of Chinese Academy of Sciences.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1.57
|
|||||
| Structure |
|
|||||
| Antibody Name |
Zilovertamab
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
TE-VC-PAB
|
Linker Info | ||||
| Conjugate Type |
Direct preparation of site-specific ADC with unpurified antibodies in culture medium.
|
|||||